CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
RAS mutation prevalence among patients with metastatic colorectal cancer: A meta-analysis of real-world data
Authors
G. Kafatos Niepel, D. Lowe, K. Jenkins-Anderson, S. Westhead, H. Garawin, T. Traugottová, Z. Bilalis, A. Molnar, E. Timar, J. Toth, E. Gouvas, N. Papaxoinis, G. Murray, S. Mokhtar, N. Vosmikova, H. Fabian, P. Skalova, A. Wójcik, P. Tysarowski, A. Barugel, M. Van Krieken, J.H. Trojan, J.
Publication date
1 January 2017
Publisher
Abstract
Aim: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. Materials & methods: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. Results: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources. Conclusion: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research. © 2017 Future Medicine Ltd
Similar works
Full text
Available Versions
Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:lib.uoa.gr:uoadl:3022005
Last time updated on 10/02/2023